Analysis of the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar

Objective: to analyze the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar.

Materials and methods: medical records of 590 children aged 1 to 5 years were analyzed. All subjects were divided into 2 groups. The first group consisted of vaccinated children (n = 490), born in 2014, and vaccinated against pneumococcal 13-valent vaccine Prevenar. The second group consisted of unvaccinated children (n = 100) born in 2013 and not vaccinated. Each group was divided into subgroups depending on the age period (1—2 years, 2—3 years, 3—4 years, 4—5 years).

Results: it is established that the conduct of specific prophylaxis of pneumococcal infection vaccine Prevenar-13 in children during the first 4 years of life effectively reduces the incidence of community-acquired pneumonia (in 7,6 times) and acute otitis media (in 8,5 times). The effectiveness of the vaccine was observed in all age groups. In cases of development of an inoculated child acute otitis reduces the risk of severe forms and complications of the disease. Analysis of the course of the post-vaccination period indicates a high level of safety and good tolerability of the vaccine.

Conclusion: Implementation of specific prophylaxis of pneumococcal 13-valent vaccine Prevenar in children during the first four years of life according to the calendar of vaccination effectively reduces the incidence of community-acquired pneumonia (87 %) and acute otitis media (42,8 %) in all age subgroups. In cases of development of an inoculated child acute otitis reduces the risk of severe forms and complications of the disease. Analysis of the course of the post-vaccination period indicates a high level of safety and good tolerability of the vaccine.

1. Kravchenko NA, Gavrilov TA, Khakimov MI Kazanova VB, Vasil'eva EI, Botvinkin AD. The Experience of a Comparative Analysis of the Incidence of Pneumonia and Acute Respiratory Infections of the Upper Respiratory Tract after the Introduction of a System of Epidemiological Monitoring of Pneumonia. Epidemiology and Vaccinal Prevention. 2019;18(1):96-104. (in Russ.). doi:10.31631/2073-3046-2019-18-1-96-104

2. Gaparkhoeva ZM, Bashkina OA, Seliverstova EN. Comparative characteristics of bronchial obstruction formation trigger mechanisms in children with bronchial asthma and recurrent obstructive bronchitis. Kazan medical journal. 2016;97(1):66-69. (in Russ.). doi:10.17750/KMJ2016-66

3. Babachenko IV, Samodova OV, Anokhin VA, Mikhaylova EV ,Bogdanova AV, EvdokimovKV, et al.Clinical and epidemiological characteristics of respiratory syncytial virus infection in children the first year of life.Journal Infectology.2018;10(3):70-76. (in Russ.). doi.10.22625/2072-6732-2018-10-3-70-76

4. Smirnova AO. Identification methods of streptococcus pneumoniae and description its serotype belonging. Journal Adnvancesin Chemistry and Chemical Technology. 2017;31(9):8-10. (in Russ.).

5. Lazareva MA, Kulichenko TV, Alyab'eva NM, Ponomarenko OA, Lazareva AV, Katosova LK, et al. Nasopharyngeal Carriage of Streptococcus pneumoniae in Orphans, Preschool Children and Unorganized Children under 5 Years. Current Pediatrics. 2015;14(2):246-255. (in Russ.). doi: 10.15690/vsp.v14i2.1293

6. Murav'ev AA, Kozlov RS, Lebedeva NN. Epidemiology of S. pneumoniae serotypes in the Russian Federation. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2017;19(3):200-206. (in Russ.).

7. Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18(1):318. doi: 10.1186/s12913-018-3139-1.

8. Fedoseenko MV, Karneeva OV, Galitskaya MG, Polyakov DP, Gayvoronskaya AG. Acute otitis media among children. Modern approach to the problem. Vaccine prevention opportunities. Pediatric pharmacology 2008;5(4):25-29. (in Russ.).

9. Grant LR, Hammitt LL, O’Brien SE, Jacobs MR, Donaldson C, Weatherholtz RC, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage among American Indians. Pediatr. Infect. Dis. J. 2016;35(8):907–914. doi: 10.1097/INF.0000000000001207

10. Jallow S, Madhi SA, Madimabe R, Sipambo N, Violari A, Kala U. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. // Vaccine. 2017;35(34):4321-4329. doi: 10.1016/j.vaccine.2017.06.081.

11. Zubova ES, Semerikov VV, Sofronova LV, Kostinov MP. 2018;17(2(99)):65-69. Assessment of Safety, Immunogenicity and Preventive Efficacy of Prevenar-13 in Children with Bronchopulmonary Dysplasia. Epidemiology and vaccinal prevention (in Russ.). doi:10.24411/2073-3046-2018-10009

12. Kharit SM, Fridman IV, Pavlyukova AN, FrolovaEYa, Ruleva AA. Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children. Pediatric pharmacology. 2016;13(5):443-447. (in Russ.).

13. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valentpneumococcalconjugate vaccine. Vaccine. 2011;29(49):9127-31. (in Russ.).doi: 10.1016/j.vaccine.2011.09.112.

14. Zhou X, de Luise C, Gaffney M, Burt CW, Scott DA, Gatto N, et al. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. Int J PediatrOtorhinolaryngol. 2019;119:96-102. doi: 10.1016/j.ijporl.2019.01.023.